Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | CES1 | P23141 | 2/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.39 |
| ▸ | MEN1 | O00255 | 7/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14350439 | 0.77 | HSD17B10 (0.39) | CA2CA9TDP1MAPTLMNA | |
| SCHEMBL10420786 | 0.76 | NOTUM (0.54) | NOTUMCA2CA9KDM4ECES1 | |
| SCHEMBL4967301 | 0.75 | KMT2A (0.44) | NOTUMKDM4ETDP1CES1MAPT | |
| SCHEMBL14575219 | 0.75 | NOTUM (0.38) | NOTUMCA2CA9KDM4ETDP1 | |
| SCHEMBL14575217 | 0.75 | NOTUM (0.38) | NOTUMCA2CA9KDM4ETDP1 | |
| SCHEMBL3319807 | 0.75 | DRD4 (0.42) | NOTUMCA2CA9KDM4ETDP1 | |
| SCHEMBL6306963 | 0.73 | LMNA (0.43) | TDP1TTRKMT2APOLBLMNA | |
| SCHEMBL2212555 | 0.71 | L3MBTL1 (0.51) | CA9KDM4ETDP1CES1MAPT | |
| SCHEMBL6280376 | 0.70 | GAA (0.37) | CA2CA9KDM4ETDP1CES1 | |
| SCHEMBL14575177 | 0.70 | CA12 (0.50) | NOTUMCA2CA9KDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9977024-B2 | Targeted covalent probes and inhibitors of proteins containing redox-sensitive cysteines | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-05-22 | — | — | US | disclosed |
| US-9977024-B2 | Targeted covalent probes and inhibitors of proteins containing redox-sensitive cysteines | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-05-22 | — | — | US | disclosed |
| US-20160195532-A1 | Targeted Covalent Probes and Inhibitors of Proteins Containing Redox-Sensitive Cysteines | THE SCRIPPS RESEARCH INSTITUTE | 2016-07-07 | — | — | US | disclosed |
| US-20160195532-A1 | Targeted Covalent Probes and Inhibitors of Proteins Containing Redox-Sensitive Cysteines | THE SCRIPPS RESEARCH INSTITUTE | 2016-07-07 | — | — | US | disclosed |
| US-8716297-B2 | Chemical entities to be used for Wee1 inhibition for the treatment of cancer | ABBVIE INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20130018045-A1 | New Chemical Entities To Be Used For Wee1 Inhibition For The Treatment Of Cancer | ABBOTT LABORATORIES (US) | 2013-01-17 | — | — | US | disclosed |
| US-8143278-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-27 | — | — | US | disclosed |
| US-20100093711-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-04-15 | — | — | US | disclosed |
| EP-2121652-A1 | 4-IMIDAZOLYL-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS ALDOSTERONE/11-BETA-HYDROXYLASE INHIBITORS | Novartis AG (CH) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008076860-A1 | 4-IMIDAZOLYL-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS ALDOSTERONE/11-BETA-HYDROXYLASE INHIBITORS | NOVARTIS AG (CH) | 2008-06-26 | — | — | WO | disclosed |
| US-4960870-A | DYEING WOOL, POLYAMIDES; FIBER REACTIVE DYES | CIBA-GEIGY CORPORATION (US) | 1990-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018045-A1 | New Chemical Entities To Be Used For Wee1 Inhibition For The Treatment Of Cancer | WEE1, WEE2, CCNE1 | NOTUM 191/4885CA2 1991/4885CA9 2358/4885 |
| US-20100093711-A1 | ORGANIC COMPOUNDS | CYP11B1, HSD11B1, CYP11B2 | NOTUM 148/4885CA2 638/4885CA9 292/4885 |
| US-20160195532-A1 | Targeted Covalent Probes and Inhibitors of Proteins Containing Redox-Sensitive Cysteines | PTMS, RSU1, QSOX1 | NOTUM 2988/4885CA2 1162/4885CA9 2663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.